Evidence reviewed: 8 November 2026. Male hypogonadism is a clinical condition involving characteristic symptoms or signs together with consistently low testosterone concentrations due to a problem affecting the testes or the hypothalamic–pituitary system. Symptoms such as fatigue, poor sleep and low mood are common and do not prove testosterone deficiency on their own. Accurate assessment requires at least two separate early-morning testosterone measurements and a search for contributing causes. The Endocrine Society’s July 2026 statement reinforces that testosterone should not be used as a nonspecific wellness or anti-aging drug, while recent FDA labeling updates clarify both cardiovascular findings and the need to monitor blood pressure [1–4].
What does testosterone do?
Testosterone is the major circulating androgen in adult men. It helps maintain sexual function, sperm-production signaling, muscle and bone health, red blood cell production and other physiological functions. Production is regulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus and luteinizing hormone (LH) from the pituitary, which stimulates testicular Leydig cells. Follicle-stimulating hormone (FSH) works with intratesticular testosterone to support spermatogenesis.
Blood testosterone is largely bound to sex hormone-binding globulin (SHBG) or albumin, with a small free fraction. SHBG changes with age, obesity, liver disease, thyroid status and certain medicines; consequently, a total testosterone result can sometimes be misleading without appropriate interpretation [2,3].
What symptoms may suggest low testosterone?
The most clinically informative symptoms often involve sexual or reproductive function:
- Reduced sexual desire (libido) or fewer spontaneous morning erections.
- Erectile difficulty, although cardiovascular, psychological, neurological and medication factors are common alternative causes.
- Reduced fertility or low sperm production in some patients.
- Loss of body or facial hair, small testes or gynecomastia in certain forms of hypogonadism.
- Low bone density, fragility fractures or unexplained anemia in appropriate clinical circumstances.
Fatigue, poor concentration, irritability, depressed mood and reduced muscle strength are nonspecific. They can arise from sleep apnea, depression, anemia, hypothyroidism, obesity, diabetes, medications and many other conditions. Diagnosing hypogonadism from a vague symptom checklist or an online “low-T quiz” risks unnecessary treatment [1–3].
When should men be tested?
The Endocrine Society recommends against routine population screening of asymptomatic men for testosterone deficiency. Testing is appropriate when there are compatible symptoms or signs and, depending on circumstances, specific disorders associated with hypogonadism. The 2026 Endocrine Society statement emphasizes that even in older men, symptoms and accurately confirmed biochemical deficiency are needed rather than simply assuming that age explains every complaint [1,2].
A clinician should review sleep, recent illness, obesity, medications, alcohol or other substances, fertility intentions, prior testicular or pituitary disease and relevant systemic symptoms before interpreting hormone results.
How should testosterone blood tests be performed?
Testosterone varies with time of day, food intake and acute illness. Use an accurate laboratory assay to measure total testosterone in the early morning, generally fasting, and repeat it on a different morning before diagnosing low testosterone or starting replacement. A single borderline result, especially in the afternoon or during an acute illness, is insufficient [1–3].
| Test | Why it is ordered | Important interpretation |
|---|---|---|
| Total testosterone | First-line biochemical assessment. | Usually requires two separate morning results with symptoms. |
| SHBG and calculated free testosterone | Helpful when total testosterone is borderline or SHBG is likely abnormal. | Use validated calculation or reliable methods; many direct analog free-testosterone assays are unreliable. |
| LH and FSH | Distinguish testicular from hypothalamic–pituitary causes. | High gonadotropins suggest primary failure; low/inappropriately normal values suggest secondary causes. |
| Prolactin | Evaluate selected cases of secondary hypogonadism or low libido. | Marked elevations or concerning symptoms may warrant pituitary evaluation. |
| Other targeted tests | Check relevant causes and baseline safety. | May include thyroid function, blood count, iron studies, glucose, kidney/liver function or pituitary imaging when indicated. |
The 2026 European Association of Urology (EAU) recommendations continue to emphasize morning fasting sampling, reliable assays and repeat testing. They use 12 nmol/L (approximately 346 ng/dL) as a threshold in the context of late-onset hypogonadism evaluation, while many US clinical recommendations use a threshold around 300 ng/dL. These values should not be treated as interchangeable universal cutoffs; clinical context, assay, free testosterone when appropriate and the specific guideline matter [2,3].
Primary versus secondary hypogonadism
Primary hypogonadism reflects testicular dysfunction. Testosterone is low while LH and often FSH are elevated because pituitary signals increase in response to inadequate hormone production. Causes can include genetic conditions, testicular injury, chemotherapy, infection or other disorders.
Secondary hypogonadism reflects inadequate signaling from the hypothalamus or pituitary. Testosterone is low with low or inappropriately normal LH and FSH. Contributing causes include pituitary disorders, elevated prolactin, obesity, some chronic illnesses and medications such as opioids or systemic glucocorticoids [2,3].
Severe headache, visual-field changes or other pituitary hormone abnormalities require specialist assessment. Selected patients with marked secondary hypogonadism need pituitary MRI; imaging is not required simply because a man has one low testosterone result.
Can obesity or poor sleep lower testosterone?
Yes. Obesity, obstructive sleep apnea, poor sleep, severe illness and selected medications can be associated with reduced testosterone concentrations. Some cases are potentially reversible with appropriate management. The 2026 Endocrine Society statement indicates that for men with obesity-associated functional testosterone reduction and no other cause, weight loss is usually a first-line intervention [1].
Exercise, balanced nutrition, sleep management and control of diabetes or other medical conditions support general health, but no evidence-based “testosterone booster” supplement reliably replaces investigation and treatment of true hypogonadism. Over-the-counter products may be mislabeled, contaminated or contain harmful substances.
When is testosterone replacement therapy appropriate?
Testosterone replacement therapy (TRT) may benefit men with well-established hypogonadism who have compatible symptoms, repeated biochemical deficiency and an indication for treatment after assessing causes and contraindications. Benefits may include improved sexual symptoms, bone density, anemia and body composition in selected patients, but the degree of effect varies. It should not be prescribed to every older adult with fatigue or used to achieve above-normal testosterone levels [1,2].
The goals of TRT are usually to restore an appropriate physiological range and improve relevant clinical outcomes. More testosterone is not necessarily better; supraphysiological dosing can cause harm. Clinicians should provide shared decision-making about uncertain benefits, risks, monitoring and alternatives.
Forms of testosterone replacement
| Form | Considerations |
|---|---|
| Transdermal gel or solution | Applied regularly; can provide relatively stable exposure but may transfer to partners or children if instructions are not followed. |
| Intramuscular or subcutaneous injections | Interval and formulation influence testosterone peaks and troughs; monitor symptoms, levels and hematocrit. |
| Transdermal patches | Can provide steady dosing but may cause local skin reactions and may be unavailable in some regions. |
| Oral testosterone undecanoate | Available in selected jurisdictions; blood-pressure warnings, formulation-specific food instructions and monitoring matter. |
| Subcutaneous pellets | Longer-acting intervention requiring insertion; dose adjustment is less immediate and procedural complications can occur. |
No formulation is universally superior. Choice depends on access, adherence, cost, adverse effects, fertility plans and monitoring. The original article used unsupported pharmacokinetic models to predict individual hormone responses; these are not clinical substitutes for measured concentrations and symptom follow-up.
Important fertility warning: TRT can suppress sperm production
Exogenous testosterone suppresses LH and FSH through negative feedback, often reducing intratesticular testosterone and sperm production. This can cause substantial oligospermia or azoospermia and compromise fertility. The Endocrine Society recommends against initiating TRT in men planning fertility in the near term [2].
Men who hope to father children should discuss reproductive evaluation, semen analysis and fertility-preserving alternatives with an endocrinologist or reproductive urologist before treatment. Do not treat infertility with testosterone injections without specialist assessment.
What do 2025–2026 cardiovascular safety updates mean?
The TRAVERSE randomized trial, involving more than 5,200 men with confirmed hypogonadism and cardiovascular risk factors, found no meaningful increase in its primary major adverse cardiovascular-event outcome over the studied period compared with placebo. The FDA removed its earlier boxed warning language about increased major adverse cardiovascular outcomes in February 2025 but added or updated blood-pressure warnings based on ambulatory blood-pressure studies [4,5].
This does not mean TRT is free of cardiovascular risk. The Endocrine Society’s July 2026 statement highlights signals involving pulmonary embolism and fractures and emphasizes that very long-term outcomes remain incompletely defined [1]. Risks vary with formulation, patient and underlying disease.
In June 2026, the FDA also requested further label revisions, including removal of a previous “limitation of use” statement concerning age-related hypogonadism and revision of prostate safety language, based on its review of emerging evidence. These regulatory changes do not eliminate the need for accurate diagnosis, fertility counseling, prostate assessment and safety monitoring. Recommendations from specialty societies and regulatory labeling do not always use identical wording [5].
Other risks and monitoring during TRT
- Erythrocytosis: hematocrit can rise, increasing concern for hyperviscosity or thrombotic risk. A baseline and follow-up blood count are important.
- Blood-pressure increases, edema and cardiovascular considerations, especially in susceptible patients.
- Acne, oily skin, breast tenderness and possible worsening of sleep apnea.
- Suppression of sperm production, often clinically important for future fertility.
- Prostate and urinary symptom assessment when appropriate for age, risk factors and local guidance.
- Formulation-specific effects, such as injection-site reactions, gel transfer and dosing fluctuations.
Clinicians typically reassess symptoms, testosterone concentrations, hematocrit, blood pressure and adverse effects, with prostate evaluation where indicated. A significant rise in hematocrit or other safety problem may require holding or modifying therapy. Patients with conditions such as untreated severe sleep apnea, high hematocrit, uncontrolled heart failure or recent major cardiovascular events require careful consideration under current practice guidance [2].
Prostate cancer and PSA: what should men know?
Testosterone therapy may affect PSA results and prostate-related symptoms; baseline evaluation and monitoring depend on age, risk, symptoms and local protocols. TRT should not be offered without careful evaluation to patients with suspected or untreated active prostate cancer except under specialist pathways and current evidence. TRT should not be presented as proven to cause all prostate cancers or as definitively cancer-risk-free; long-term outcomes and subgroup risks remain areas of study [1,2,5].
When should testosterone be avoided or postponed?
Contraindications and precautions differ by product and guidance. Common reasons to avoid or defer routine TRT include planned fertility, unexplained high hematocrit, uncontrolled heart failure, untreated severe sleep apnea, certain prostate or breast cancers and other significant untreated medical risks. The treatment decision should involve an appropriately trained clinician rather than an online clinic offering therapy after one convenient nonfasting blood test [2].
Do testosterone “boosters” work?
Many marketed supplements promise better masculinity, libido or muscle growth but lack convincing clinical evidence of restoring physiological testosterone in men with true hypogonadism. Some products may contain undeclared drugs, anabolic steroids or harmful ingredients. Treat a genuine underlying deficiency or illness through an evidence-based pathway rather than high-dose herbs or unregulated products.
Frequently asked questions
Can fatigue alone diagnose low testosterone?
No. Symptoms are nonspecific; diagnosis needs clinical assessment and repeated low morning testosterone results [1–3].
Is a single testosterone value below 300 ng/dL always enough?
No. Test timing, assay, repeat confirmation, SHBG and clinical context matter. Thresholds vary between guidelines.
Can TRT help erectile dysfunction?
It may improve symptoms in appropriately selected men with true deficiency, but vascular and other causes of erectile dysfunction also require assessment.
Will TRT help me have children?
No. It can suppress sperm production. Discuss fertility-preserving options with a specialist before starting [2].
Did the FDA declare testosterone completely cardiovascular-risk-free?
No. Label changes reflect trial evidence on major adverse cardiovascular events, while blood-pressure and other safety concerns remain [1,4,5].
Is TRT a standard anti-aging treatment for healthy older men?
No. Specialty guidance emphasizes accurate diagnosis and targeted treatment, not population-level treatment of normal aging symptoms [1].
Key takeaways
Diagnose, do not guess. Low testosterone requires compatible symptoms and two separate early-morning measurements, with LH/FSH and other tests as indicated. TRT can benefit properly diagnosed men, but it can impair fertility and needs ongoing hematocrit, blood-pressure and other monitoring. 2025–2026 FDA updates are not a blanket guarantee of safety.
References
- Endocrine Society. Statement on testosterone replacement therapy. 16 July 2026.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715–1744. doi:10.1210/jc.2018-00229.
- European Association of Urology. Sexual and reproductive health guidelines: male hypogonadism. 2026.
- US Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. 28 Feb 2025.
- US Food and Drug Administration. Testosterone information: TRAVERSE findings and June 2026 updates. Accessed 8 Nov 2026.
Medical disclaimer: Educational material only. Testosterone is a prescription medication with fertility, cardiovascular, hematologic and other potential risks. Testing, selection and monitoring should be supervised by qualified clinicians. Never begin TRT or unregulated supplements based on a single blood test or online symptom checklist.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.